Thanks for your question. First, let me request that if any of the
following is unclear or if you require any further research please
dont hesitate to ask me for a clarification.
You requested a list of all venture capital firms with a significant
Involvement in biotechnology which are located in the Bay Area (San
Francisco, Palo Alto, Menlo Park, etc.), along with a brief
description of each firm as well as a link to their web pages.
Ive identified the following firms -
Combined venture capital and management firm specializing in biotech.
Advanced Technology Ventures
Focuses on early-stage companies, and has invested in a number of
diagnostics manufacturers as well as makers of minimally invasive
surgical instruments and intracoronary radiation systems.
Experienced in IT and health care. Successes include Remedy, Amgen,
Pharmacyclics, Archive (Conner), Applied Biosystems (PE Biosystems),
Octel (Lucent), InPart (Parametric), Sapient (Healtheon/WebMD), and
Alta Partners was founded in 1996 by four of the senior partners of
Burr, Egan, Deleage & Co. (BEDCO), a pioneering venture capital firm
formed in 1979 that focused on early-stage investing in life sciences,
information technology and communications. Alta currently manages five
venture fund programs aggregating approximately $1 billion in
committed capital. Since 1996, we have funded approximately 120 life
sciences and information technology companies.
Asset Management Associates
Invests in diagnostics manufacturers and life sciences companies.
Usually invests about $2 million to $3 million during the seed or
BioAsia Investments LLC
BioAsia Investments is a California-based venture investment limited
liability company formed in 1997 for the purpose of managing the
Biotechnology Development Funds, which invest in life sciences and
healthcare information companies.
Since 1982, Charter Venture Capital has been an active and dedicated
force in the growth of Silicon Valley, helping entrepreneurs turn
great ideas into great companies. Its partners provide hands-on
guidance and valued-added expertise to co-pilot the growth of a select
group of emerging companies. The firm's balanced portfolio of
communications, software and life sciences companies is strategically
designed to provide solid long-term returns and weather economic
changes. To date, more than 50 Charter-backed companies have completed
initial public offerings and mergers & acquisitions transactions.
CMEA Ventures is a San Francisco based venture capital firm that was
established in 1989 and specializes in high technology and life
sciences investments. We invest in both early and late stage
companies, and actively partner with our extended network of
companies, other VC firms, institutional investors, strategic partners
as well as entrepreneurs.
Under the leadership of Jean-Pierre L. Conte , Richard F. Hoskins and
Richard D. Paterson , Genstar Capital has had a long history of
investing in companies active in dynamic markets, including life
sciences, information technology and industrial technology. In July
2001, the firm held the final closing for Genstar Capital Partners
III, L.P. for a total of $221 million, adding to the over $220 million
in commitments that were made in the first two funds.
InterWest Partners, founded in 1979, is a leading diversified venture
capital firm currently investing InterWest VIII, a $750 million fund.
We are focused on building long-term relationships with entrepreneurs
and portfolio companies. Our experienced partners, who bring together
deep domain knowledge in information technology and life sciences,
have established a proven track record of identifying, validating and
backing emerging trends and technologies. With $1.6B capital under
management, we take a long-term, collaborative approach to venture
funding, providing early stage and ongoing capital, management
coaching and access to a broad network of resources.
IVP-Institutional Venture Partners
IVP was founded in 1980 and has more than $1.3 billion of committed
capital. Having funded more than 200 companies, IVP is proud of its
track record of more than 75 IPOs. IVP has consistently funded
companies that have become market leaders in new industries:
 Communications Equipment: Bay Networks, MMC Networks,
 Computing: Stratus, Sequent
 Enterprise Software: Clarify, Concur
 Internet: Ask Jeeves, Concur, Excite, Mpath
 Life Sciences: Aviron, Biopsys
 Semiconductors: LSI Logic, Altera, Atmel, Cirrus Logic,
 Storage: Seagate, Exabyte
In aggregate, IVPs portfolio companies have revenues of more than $25
billion, a combined market value of more than $75 billion and employ
over 150,000 people.
Magic Venture capital
MVC IS FOCUSED on providing seed and first round funding for
healthcare ventures, and distinguishes itself from other venture
capital groups in that the partners will avail themselves for hands-on
management and operations. This partnership between MVC and the
founders will enable the venture to grow at an accelerated pace.
Menlo Ventures provides long-term capital and management support to
early-stage and emerging-growth companies. We are one of Silicon
Valley's oldest venture capital partnerships, and have organized and
managed nine venture funds since our inception in 1976. With over $2.7
billion under management, and a team with over one hundred years of
collective experience in technology, marketing, sales and general
management, we have the resources to support the most ambitious of
Morgenthaler Ventures has worked with outstanding entrepreneurs to
build world-class companies for over 34 years. As active investors,
Morgenthaler has completed at least one new investment per month since
January 2000. Our passion for company building has earned us the
respect of our partners and exceptional results for our investors. We
have $2 billion under management, including $850 million in our
current fund (capitalized in the summer of 2001). We have partnered
with entrepreneurs in more than 180 companies since the firm's
founding in 1968. Our team focuses on enterprise IT, life sciences,
semiconductor and components, and broadband communications companies.
We are headquartered in Menlo Park, CA, with offices in Boulder, CO;
Boston, MA; Dallas, TX; and Princeton, NJ.
New Enterprise Associates
Founded in 1978, NEA has grown to eleven partnerships managing $5
billion of capital. We are classic venture capital investors,
concentrating on early stage companies in the areas of information
technology and medical and life sciences. We typically invest in 20
to 30 new companies each year. Our first investment can be as little
as $200,000 or up to $20 million, and we typically support our
companies through multiple rounds of financing.
Pacific Venture Group (PVG)
Pacific Venture Group was founded in 1995 as a privately held venture
capital partnership focused exclusively on investments in the
healthcare industry. The firm currently manages two venture funds
whose limited partners include pension funds, financial institutions,
and healthcare companies. In addition, the firm manages side-by-side
funds consisting of limited partners who are leading healthcare
entrepreneurs and executives.
Pacific Venture Group's Managing Directors are senior executives who
are active lead investors in the fund's portfolio companies. Our
Managing Directors' in-depth operational knowledge and contacts in
both the healthcare and the financial industries provide significant
assistance to entrepreneurial management teams as they work to grow
and expand their businesses.
The funds typically invest from $2 to $5 million but may ultimately
invest as much as $10 million over the life of a company. In the case
of our funding a seed stage company, our investment can be as low as
$250,000. In addition, strong relationships with our healthcare
oriented limited partners often provides for additional equity or debt
funding. Finally, the firm has well-established relationships with
other equity and debt sources including other venture firms,
commercial and investment banks
Sanderling Biomedical Venture Capital
Founded in 1979, Sanderling is among the oldest investment firms
dedicated to building new biomedical companies. Sanderling
demonstrates that significant companies are best built in close
working partnerships with entrepreneurs.
Sanderling's unique approach combines a specialized investment focus
with active management and long-term commitment to ensure the highest
rates-of-return for both its entrepreneurs and investors.
Biomedical investing has been a viable sector in the technology
markets for more than thirty years, and in the past ten years has
experienced accelerated growth. Since its inception, Sanderling has
supported over 40 biomedical companies from very early stages through
commercial development, earning consistently high rates-of-return on
its venture investments.
Sanderling emphasizes early-stage financing and active management of
its portfolio companies. Sanderling and its principals play an active
role in new ventures by providing seed and early-stage funding,
contributing management leadership and administrative support,
developing cost-control strategies to extend available dollars,
supplying technical and regulatory expertise where needed, and
offering the insight and perspective of those who have "done it
before." The Partnership has sufficient capital to support the
companies in later-stage financing, protecting its investments from
Skyline Ventures, formed in 1997, is a nationally known firm that
specializes in hands-on investing in early stage healthcare companies.
Our initial investment is usually made at the time of a companys
first venture round, and we often become the lead investor. In
addition, we occasionally roll up our sleeves and help scientists or
engineers found a company, helping them turn good ideas that are too
unformed to be financeable into exciting projects that are
subsequently financed by major venture capital firms or financial
institutionsa successful approach that we call Sweat Stage Venture
Capital. Skyline focuses on drug discovery tools, biotechnology,
medical devices and healthcare information technology. We have
approximately 20 companies in our portfolio, including a handful we
have help found and more than a dozen in which we have played an
active, albeit non-founding role.
The firm currently has $250 million under management. Skyline I, II
and III are dedicated to early stage healthcare investing, including
follow-on rounds, using the strategy above. The Skyline Expansion Fund
invests in companies in the Skyline I, II and/or III portfolios, and
allows Skyline to enhance our ability to back our portfolio companies
heavily in follow-on rounds.
Technology Partners teams with visionary entrepreneurs to build
successful new companies. We serve principally as a lead investor and
business adviser to technology-based ventures in our focus areas of
next generation enterprise software, energy technology, biotechnology
and medical devices, in particular interventional cardiology and
Founded in 1980 as a private venture capital firm, Technology Partners
manages a total of more than $400 million of investment capital.
Investments are being made currently from Technology Partners Fund
VII, L.P., formed in 2000 with approximately $250 million of capital.
US Venture Partners
US Venture Partners (USVP) is a venture capital firm that is dedicated
to helping entrepreneurs realize their dreams of building world class
companies that are leaders in their industry. We believe deeply in the
value created by the entrepreneurial process and in the relentless
pursuit of opportunity. We enjoy the challenge of aiming high and
believe that by pursuing lofty goals, we will ultimately generate the
greatest returns for our investors.
Since inception in 1981, USVP has raised more than $2.5 billion in
eight funds, including a $1 billion fund that closed in January 2001.
To date, over $1.1 billion has been invested in more than 271
companies. Many of these companies where USVP was the "founding" lead
investor, such as Sun Microsystems, New Focus, Check Point Software
Technologies, Nuance Communications, Blue Martini Software, AMCC, MMC
Networks, Centillium Communications, Stratacom/Cisco, and CacheFlow
have become the leading companies in their respective fields. In fact,
68 USVP portfolio companies are now public companies with an aggregate
market capitalization of over $313 billion. These 68 companies
generate more than $26 billion in annual revenue and employ more than
83,000 people. Many others have been acquired and become part of
industry leading companies. We are very proud to have been associated
with such remarkable entrepreneurial successes
Vanguard Venture Partners
Vanguard Ventures is a leading early stage venture capital firm that
helps entrepreneurs build pioneering technology and life science
companies. Each Vanguard partner brings hands-on entrepreneurial
experience to the firm, as well as executive and venture capital
Each of our partners has unique expertise and interests, and, together
with our network of affiliates, provides meaningful support and
assistance to our portfolio companies.
Over the last 21 years, Vanguard Ventures has invested in over 115
companies, 30 of which have had notable success, including public
companies such as Advanced Fibre Communications, Cobalt Networks,
Ciena, Endotherapeutics, Network Appliance and Digital Island. With
each of these companies, we invested in their first round of venture
I hope this response adequately addresses your request. Please let me
know if you are in need of additional information concerning this
A great source for searching for and identifying various entities in
the biotech space is -
Other Relevant Google Answers Responses:
US Venture Capital firms
Top Health Care Venture Capital Firms
Biotech venture capital California